-
公开(公告)号：KR1020160141595A
公开(公告)日：2016-12-09
申请号：KR1020150077504
申请日：2015-06-01
Applicant: 삼성전자주식회사
IPC: H04L12/58
CPC classification number: H04M3/42017 , G06F17/278 , G06F17/28 , G06F17/289 , G10L13/033 , G10L13/08 , G10L21/007 , H04L51/04 , H04L51/063 , H04L51/12 , H04L51/32 , H04M3/42
Abstract: 전자장치의제어방법이개시된다. 전자장치의제어방법은, 송신자로부터의메시지를획득하는동작, 상기메시지의수신자를식별하는동작, 상기송신자및 상기수신자사이의제 1 관계정보와, 상기수신자및 상기전자장치사이의제 2 관계정보에기초하여상기메시지를변환하는동작및 상기변환된메시지를출력하는동작을포함할수 있다.
Abstract translation: 提供了一种用于控制电子设备的方法。 该方法包括从发送方获取消息，识别消息的接收方，基于发送方与接收方之间的第一关系信息以及接收方与电子装置之间的第二关系信息来转换消息，并输出转换的消息。
-
-
公开(公告)号：KR1020150028652A
公开(公告)日：2015-03-16
申请号：KR1020130107568
申请日：2013-09-06
Applicant: 삼성전자주식회사
IPC: A61K39/395 , A61K48/00 , A61P35/00
CPC classification number: A61K39/39558 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/519 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/74 , C12N15/113 , C12N2310/14 , C12N2320/31 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition for combination therapy for preventing and/or treating cancer comprising a c-Met inhibitor and a beta-catenin inhibitor as active ingredients, to use of c-Met inhibitor efficacy enhancement by the beta-catenin inhibitor, and use of beta-catenin inhibitor efficacy enhancement by the c-Met inhibitor. The combination therapy of the c-Met inhibitor and beta-catenin inhibitor enables treatment of diseases which could not be treated by the c-Met inhibitor alone, thereby extending indications and overcoming resistance against the c-Met inhibitor.
Abstract translation: 本发明涉及一种用于预防和/或治疗癌症的组合治疗药物组合物，其包含c-Met抑制剂和β-连环蛋白抑制剂作为活性成分，以使用由β-连环蛋白抑制剂提高c-Met抑制剂功效， 并通过c-Met抑制剂使用β-连环蛋白抑制剂的功效增强。 c-Met抑制剂和β-连环蛋白抑制剂的联合治疗能够治疗单独用c-Met抑制剂治疗的疾病，从而延长适应症并克服对c-Met抑制剂的抵抗力。
-
公开(公告)号：KR1020140119661A
公开(公告)日：2014-10-10
申请号：KR1020140038839
申请日：2014-04-01
Applicant: 삼성전자주식회사
IPC: A61K39/395 , C07K16/28 , A61P35/00
CPC classification number: A61K39/39558 , A61K31/4412 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/92 , A61K2300/00
Abstract: Provided is a pharmaceutical composition containing anti-c-Met antibody and sorafenib as active ingredients for a combination therapy for preventing and/or treating cancer diseases. The pharmaceutical composition for a combination therapy has an excellent synergistic effect and can reduce the effective dose of the anti-c-Met antibody, thereby can more effectively treat the cancer.
Abstract translation: 提供含有抗c-Met抗体和索拉非尼作为预防和/或治疗癌症疾病的组合疗法的活性成分的药物组合物。 用于联合治疗的药物组合物具有优异的协同效应，并且可以降低抗c-Met抗体的有效剂量，从而可以更有效地治疗癌症。
-
公开(公告)号：KR1020140119623A
公开(公告)日：2014-10-10
申请号：KR1020130161685
申请日：2013-12-23
Applicant: 삼성전자주식회사
IPC: A61K39/395 , A61P35/00
CPC classification number: A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2300/00
Abstract: Provided is a pharmaceutical composition containing anti-c-Met antibody and FGFR inhibitor as active ingredients for a combination therapy for preventing and/or treating cancer diseases. The pharmaceutical composition for a combination therapy has an excellent synergistic effect and can reduce the effective dose of the anti-c-Met antibody, thereby can more effectively treat the cancer.
Abstract translation: 提供含有抗c-Met抗体和FGFR抑制剂作为预防和/或治疗癌症疾病的组合疗法的有效成分的药物组合物。 用于联合治疗的药物组合物具有优异的协同效应，并且可以降低抗c-Met抗体的有效剂量，从而可以更有效地治疗癌症。
-
Patent Agency Ranking
公开(公告)号：KR1020140035266A
公开(公告)日：2014-03-21
申请号：KR1020130108913
申请日：2013-09-11
Applicant: 삼성전자주식회사
IPC: A61K39/395 , A61K47/48 , A61P35/00
CPC classification number: A61K39/3955 , A61K45/06 , C07K16/2863 , C07K2317/24
Abstract: Provided is a pharmaceutical composition for a combination therapy which contains an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof as an active ingredient for preventing and/or treating c-Met and angiogenic factor induced diseases. The pharmaceutical composition for the combination therapy has a superior synergistic effect, thereby more effective treatments are available.
Abstract translation: 提供了含有血管生成抑制剂和抗c-Met抗体或其抗原结合片段作为预防和/或治疗c-Met和血管生成因子诱导的疾病的活性成分的药物组合物。 用于联合治疗的药物组合物具有优异的协同效应，从而可获得更有效的治疗。
-
公开(公告)号：KR1020110002750A
公开(公告)日：2011-01-10
申请号：KR1020090060388
申请日：2009-07-02
Applicant: 삼성전자주식회사
IPC: C09K9/02
CPC classification number: C07D213/22 , C07F9/581
Abstract: PURPOSE: An electrochromic material is provided to ensure high operation voltage and wide potential window range and to secure excellent stability and reliability. CONSTITUTION: An electrochromic material includes at least one selected from electrochromic materials represented by chemical formula 1 - 3. The electrochromic material includes a first electrode and a second electrode which are faced with each other, an electrochromic material layer containing the electrochromic material positioned between the first electrode and the second electrode, and an electrolyte layer located between the first electrode and the second electrode.
Abstract translation: 目的：提供电致变色材料，以确保高操作电压和宽电势窗范围，并确保优异的稳定性和可靠性。 构成：电致变色材料包括选自由化学式1-3表示的电致变色材料中的至少一种。电致变色材料包括彼此面对的第一电极和第二电极，含有电致变色材料的电致变色材料层位于 第一电极和第二电极，以及位于第一电极和第二电极之间的电解质层。
-
公开(公告)号：KR1020100027510A
公开(公告)日：2010-03-11
申请号：KR1020080086451
申请日：2008-09-02
Applicant: 삼성전자주식회사
CPC classification number: C07D401/14 , C07F9/65583 , G02F1/1521 , G02F2202/36
Abstract: PURPOSE: An electrochromic material is provided to implement RGB Full Color because the electrochromic material can realize various colors, and to be used for various electrochromic devices. CONSTITUTION: An electrochromic material has a structure represented by chemical formula 1 or 2. In chemical formula 1 or 2, R1 and R2 are independently hydrogen, halogen, CN, OH, COOH, C1-20 alkyl or cycloalkyl, C2-20 alkenyl, C1-20 alkoxy or C5-12 aryl; X is halides, PF6^-, BF4^-, BH4^-, or CF3SO3^-; and R3 is C1-20 alkyl or cloalkyl, C2-20 alkenyl, C1-20 alkoxy, C5-12 aryl, C5-12 heteroaryl, carbazole, fluorine or spirofluorene.
Abstract translation: 目的：提供电致变色材料以实现RGB全色，因为电致变色材料可以实现各种颜色，并用于各种电致变色设备。 构成：电致变色材料具有由化学式1或2表示的结构。在化学式1或2中，R 1和R 2独立地为氢，卤素，CN，OH，COOH，C 1-20烷基或环烷基，C 2-20烯基， C 1-20烷氧基或C 5-12芳基; X是卤化物，PF 6 - ，BF 4 - ，BH 4 - 或CF 3 SO 3 - 。 且R 3为C 1-20烷基或C 1-4烷基，C 2-20烯基，C 1-20烷氧基，C 5-12芳基，C 5-12杂芳基，咔唑，氟或螺芴。
-
公开(公告)号：KR1020100020417A
公开(公告)日：2010-02-22
申请号：KR1020090041603
申请日：2009-05-13
Applicant: 삼성전자주식회사 , 성균관대학교산학협력단
CPC classification number: C09K9/02 , C09K2211/1007 , C09K2211/1092
Abstract: PURPOSE: An electrochromic material is provided to realize various colors, to ensure bistability, and to enable the implementation of full-color, and to be variously used for various electrochromic electronics. CONSTITUTION: An electrochromic material comprises a compound represented by chemical formula 1. In chemical formula 1, R1 is single bond C6-50 aryl group, C5-50 hetero aryl group, thienyl group, bithienyl group, C2-20 alkenyl group conjugated with S, O or isophthalate groups, C2-20 alkynyl group, C3-20 alkenylalkynyl, C3-20 alkynylalkyl or C4-20 alkenylalkynyl group; R2 is -(CH2)m-; m is an integer of 1-10; and R3 is H, -CH=CH2, 1, 2-ethanediol group, C1-10 linear, branched or cyclic alkyl group, C2-10 linear and branched alkenyl group, C6-12 aryl group, C5-12 heteroaryl group, carboxylic acid group or phosphonic acid group.
Abstract translation: 目的：提供电致变色材料，以实现各种颜色，确保双稳态，并实现全彩色，并可用于各种电致变色电子设备。 构成：电致变色材料由化学式1表示的化合物构成。化学式1中，R1为单键C6-50芳基，C5-50杂芳基，噻吩基，双噻吩基，与S结合的C2-20烯基 ，O或间苯二甲酸酯基，C 2-20炔基，C 3-20烯基炔基，C 3-20炔基烷基或C 4-20烯基炔基; R2是 - （CH2）m-; m为1-10的整数; 且R 3为H，-CH = CH 2，1,2-乙二醇基，C 1-10直链，支链或环状烷基，C 2-10直链和支链烯基，C 6-12芳基，C 5-12杂芳基，羧酸 酸基或膦酸基。
-
公开(公告)号：KR1020090105794A
公开(公告)日：2009-10-07
申请号：KR1020080122128
申请日：2008-12-03
Applicant: 삼성전자주식회사 , 성균관대학교산학협력단
IPC: C09K9/02
Abstract: PURPOSE: An electrochromic material is provided to be useful for various electrochromic devices by implementing RGB full-color. CONSTITUTION: An electrochromic material represented by the following formula (1), wherein R1 is selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a cyano group, a nitro group, a carboxyl group, a benzoylamino group, a C1-C50 alkylsulfonylamino group, a C1-C50 linear alkyl group, a C1-C50 branched alkyl group, a C1-C50 cyclic alkyl group, a C2-C50 linear alkenyl group, a C2-C50 branched alkenyl group, a C2-C50 linear alkynyl group, a C2-C50 branched alkynyl group, a C1-C50 alkoxy group, a C2-C50 alkylalkoxy group, a C6-C50 aryl group, a C5-C50 heteroaryl group, and a thienyl group, wherein the branched alkyl group, the cyclic alkyl group, the branched alkenyl group, the aryl group and the heteroaryl group is unsubstituted or substituted with at least one group selected from halo, hydroxyl, amino, cyano, nitro, thienyl, C1-C7 alkyl and C2-C7 alkenyl groups, wherein each R2 is -(CH2)m-, wherein m is an integer from 1 to 10, and wherein each R3 is selected from the group consisting of -CH-CH2, a C1-C10 linear alkyl group, a C1-C10 branched alkyl group, a C1-C10 cyclic alkyl group, a C2-C10 linear alkenyl group, a C2-C10 branched alkenyl group, a C6-C12 aryl group, and a C5-C12 heteroaryl group.
Abstract translation: 目的：提供电致变色材料，可用于各种电致变色设备，通过实施RGB全彩色。 构成：由下式（1）表示的电致变色材料，其中R1选自氢原子，卤素原子，羟基，氨基，氰基，硝基，羧基 苯甲酰基氨基，C 1 -C 50烷基磺酰基氨基，C 1 -C 50直链烷基，C 1 -C 50支链烷基，C 1 -C 50环烷基，C 2 -C 50直链烯基，C 2 -C 50支链烯基 基团，C2-C50直链炔基，C2-C50支链炔基，C1-C50烷氧基，C2-C50烷基烷氧基，C6-C50芳基，C5-C50杂芳基和噻吩基 其中支链烷基，环烷基，支链烯基，芳基和杂芳基是未取代的或被至少一个选自卤素，羟基，氨基，氰基，硝基，噻吩基，C 1 -C 7 烷基和C 2 -C 7烯基，其中每个R 2是 - （CH 2）m - ，其中m是1至10的整数，并且其中 每个R 3选自-CH-CH 2，C 1 -C 10直链烷基，C 1 -C 10支链烷基，C1-C10环烷基，C2-C10直链烯基，C2- C10支链烯基，C6-C12芳基和C5-C12杂芳基。
-
-
-
-
-
-
-
-
-
Search Results
51
records
(took 0.046 seconds)
